Recertification for CDC STD/TB and HRSA Ryan White Program entities will be delayed until the first quarter of 2014. Please continue to review your covered entity’s records in the 340B Program database for accuracy to ensure that your authorizing official receives their user name and password at the appropriate time; access for STD and TB entities to submit electronic change requests has been restored. We also suggest working with your IT departments to ensure that spam filters will not block emails from 340B.Recertification@hrsa.gov or other hrsa.gov addresses.
For general 340B registration and recertification questions please contact the 340B Prime Vendor Program at ApexusAnswers@340bpvp.com or 1-888-340-2787. We apologize for any inconvenience you may experience as a result of the delay.
The 340B Drug Pricing Program requires drug manufacturers to provide outpatient drugs to eligible health care organizations/covered entities at significantly reduced prices.
The 340B Program enables covered entities to stretch scarce Federal resources as far as possible, reaching more eligible patients and providing more comprehensive services.
Eligible health care organizations/covered entities are defined in statute and include HRSA-supported health centers and look-alikes, Ryan White clinics and State AIDS Drug Assistance programs, Medicare/Medicaid Disproportionate Share Hospitals, children’s hospitals, and other safety net providers. See the full list of eligible organizations/covered entities.
To participate in the 340B Program, eligible organizations/covered entities must register and be enrolled with the 340B program and comply with all 340B Program requirements. Once enrolled, covered entities are assigned a 340B identification number that vendors verify before allowing an organization to purchase 340B discounted drugs.
New registrations are accepted October 1-15, January 1-15, April 1-15 and July 1-15.
Program Audit Results updated 11/04/2013 (PDF - 213 KB)
340B Peer-to-Peer Program 9/30/2013
GSK Notice to 340B Covered Entities (PDF - 345 KB) 9/17/2013
Onyx Pharmaceutical Notice of Refund (PDF - 189 KB) 9/05/2013
Notice Regarding Recalculated 340B Ceiling Prices for Genentech Products (PDF - 207 KB) 08/2013
Policy Release Updates
340B Glossary of Terms (PDF - 299 KB)